Biosafety assays for the diagnosis and prediction of drug-related complement pathology

Project Information

Biosafety

Grant agreement ID: 952520

DOI

10.3030/952520

Project closed

EC signature date 6 July 2020

Start date 1 September 2020

End date 31 August 2023

Funded under

• Twinning of research institutions

Total cost

€ 900 000,00

EU contribution

€ 900 000,00

Coordinated by

SEMMELWEIS EGYETEM
Hungary

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (8)

“BIOSAFETY” Joint Summer School (A and B)

A joint summer school will be organised in Budapest

Report about the meetings with interest groups from industry

Meetings with interest groups from industry will be reported

KPIs definition for “BIOSAFETY”

This list of putative KPIs will be thoroughly discussed with the expert partnering institutions and a final list will be compiled

Impact assessment by the end of the project and forecast of the following 3-year period

Impact assessment will be performed in a 3year window by the end of the project

"„The industrial day"" and ""Knowledge Transfer Zone"" through meetings between research institutions and enterprises"

Experts from the partnering institutions will be invited to provide inspirational lectures and topic related events to stimulate brainstormingExperts from the partnering institutions will be invited to provide inspirational lectures and topic related events to stimulate brainstorming

Impact assessment in the 3-year period prior to “BIOSAFETY” for all KPIs

Impact assessment will be performed in a 3year window at the begining of the project

Publication history of Semmelw in the last 3 years
“BIOSAFETY” Thematic Workshop (A and B)

Thematic workshop for example biosafety markers un indispensable tool to predict unwanted side effects relevant to BIOSAFETY project will be organised

Open Research Data Pilot (2)

First data Management Plan
Final Data Management Plan

Websites, patent fillings, videos etc. (1)

Development of the project logo/brand and brochure/flyer

Developing a project logo and setting up a project website are two critical steps which will pave the way for an effective Public Relations PR strategy for BIOSAFETYA brochure and flyer will also be developed in the first year of the project to support the dissemination of BIOSAFETY in different events They will be revised when needed

Publications

Peer reviewed articles (15)

Effect of the Addition of Alginate and/or Tetracycline on Brushite Cement Properties

Author(s): Claudia Morilla, Elianis Perdomo, Ana Karla Hernández, Ramcy Regalado, Amisel Almirall, Gastón Fuentes, Yaima Campos Mora, Timo Schomann, Alan Chan, Luis J. Cruz
Published in: Molecules, Issue 26/11, 2021, Page(s) 3272, ISSN 1420-3049
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/molecules26113272

Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy

Author(s): Yang Hao,Chih Kit Chung,Zhenfeng Yu,Ruben V. Huis in ‘t Veld,Ferry A. Ossendorp,Peter ten Dijke,and Luis J. Cruz.
Published in: Pharmaceutics, 2022, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14010120

A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor

Author(s): Dezsi L, Meszaros T, Kozma GT, H-Velkei M, Olah CZ, Szabo M, Patko Zs, Fulop T, Hennies M, Szebeni M, Barta BA, Merkely B, Radovits T, and Szebeni J
Published in: GeroScience, Issue 44(2), 2022, Page(s) 597–618, ISSN 2509-2723
Publisher: Springer
DOI: 10.1007/s11357-021-00495-y

Zinc-Phthalocyanine-Loaded Extracellular Vesicles Increase Efficacy and Selectivity of Photodynamic Therapy in Co-Culture and Preclinical Models of Colon Cancer

Author(s): Pablo Lara, Ruben V. Huis in ‘t Veld, Carla Jorquera-Cordero, Alan B. Chan, Ferry Ossendorp, Luis J. Cruz
Published in: Pharmaceutics, Issue 13/10, 2021, Page(s) 1547, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13101547

The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue

Author(s): Campos, Yaima; Fuentes, Gastón; Almirall, Amisel; Que, Ivo; Schomann, Timo; Chung, Chih Kit; Jorquera Cordero, Carla; Quintanilla Sierra, Luis; Rodríguez Cabello, José Carlos; Chan, Alan; Cruz, Luis
Published in: Pharmaceutics, Issue 1, 2022, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14020282

Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines

Author(s): Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Crommelin DJA and Dobrovolskaia MA
Published in: Nature Nanotechnology, Issue 17(4), 2022, Page(s) 337-346, ISSN 1748-3387
Publisher: Nature Publishing Group
DOI: 10.1038/s41565-022-01071-x

Eculizumab suppresses zymosan-induced release of inflammatory cytokinesIL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures:Relevance to cytokine storm in Covid-19

Author(s): Bakos T. Kozma GT, Szebeni J, Szénási G.
Published in: Biomedicine & Pharmacotherapy, Issue 166, 2023, Page(s) 115294, ISSN 0753-3322
Publisher: Elsevier Masson
DOI: 10.1016/j.biopha.2023.115294

Zymosan Particle-Induced Hemodynamic, Cytokine and Blood Cell Changes in Pigs: An Innate Immune Stimulation Model with Relevance to Cytokine Storm Syndrome and Severe COVID-19

Author(s): Kokeny G, Bakos T, Barta BA, Nagy GV, Meszaros T, Kozma GT, Szabo A, Szebeni J, Merkely B, Radovits T
Published in: International Journal of Molecular Sciences, Issue 24, 2023, Page(s) 18, ISSN 1661-6596
Publisher: MDPI
DOI: 10.3390/ijms24021138

Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion

Author(s): Gergely Milosevits,Tamás Mészáros, Erik Őrfi PharmD, Tamás Bakos, Miklós Garami, Gábor Kovács, László Dézsi, Péter Hamar, Balázs Győrffy, András Szabó, Gábor Szénási,János Szebeni.
Published in: Nanomedicine: Nanotechnology, Biology and Medicine, 2021, ISSN 1549-9634
Publisher: Elsevier BV
DOI: 10.1016/j.nano.2021.102366

Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm

Author(s): Gergely Tibor Kozma, Tamás Mészáros, Tamás Bakos, Mark Hennies, Dániel Bencze, Barbara Uzonyi, Balázs Győrffy, Edward Cedrone, Marina A. Dobrovolskaia, Mihály Józsi and János Szebeni.
Published in: Front. Immunol, Issue 12, 2021, ISSN 1664-3224
Publisher: Front. Immunol
DOI: 10.3389/fimmu.2021.642860

To “PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

Author(s): Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA
Published in: Advanced Drug Delivery Reviews, Issue 180, 2022, Page(s) 22, ISSN 0169-409X
Publisher: Elsevier BV
DOI: 10.1016/j.addr.2021.114079

The Hypertensive Effect of Amphotericin B-Containing Liposomes (Abelcet) in Mice: Dissecting the Roles of C3a and C5a Anaphylatoxins, Macrophages and Thromboxane

Author(s): Orfi E, Hricisak L, Dezsi L, Hamar P, Benyo Z, Szebeni J, Szenasi G
Published in: Biomedicines, Issue 10(7), 2022, Page(s) 1764, ISSN 2227-9059
Publisher: MDPI AG
DOI: 10.3390/biomedicines10071764

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG

Author(s): Kozma TG, Meszaros T, Berenyi P, Facsko R, Patko Zs, Oláh Cs, Nagy J, Fulop T, Glatter K, Radovits T, Merkely B, Szebeni J.
Published in: Vaccine, Issue 41, 2023, Page(s) 4561-4570, ISSN 0264-410X
Publisher: Elsevier BV
DOI: 10.1016/j.vaccine.2023.06.009

Nanocarriers as a Tool for the Treatment of Colorectal Cancer

Author(s): Ana Luiza C. de S. L. Oliveira, Timo Schomann, Lioe-Fee de Geus-Oei, Ellen Kapiteijn, Luis J. Cruz, Raimundo Fernandes de Araújo Junior
Published in: Pharmaceutics, Issue 13/8, 2021, Page(s) 1321, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13081321

Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA–Lipid Complexes

Author(s): Szebeni, J;Kiss, B;Bozo, T;Turjeman, K;Levi-Kalisman, Y;Barenholz, Y;Kellermayer, M
Published in: ACS NANO, Issue 17, 2023, Page(s) 13147-13157, ISSN 1936-0851
Publisher: American Chemical Society
DOI: 10.1021/acsnano.2c11904